

**VIA EDGAR**

February 11, 2019

United States Securities and Exchange Commission  
Division of Corporation Finance  
Mail Stop 4561  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Donald Field

**Re: TCR<sup>2</sup> Therapeutics Inc.**  
**Acceleration Request for Registration Statement on Form S-1**  
**File No. 333-229066**

Dear Mr. Field:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), TCR<sup>2</sup> Therapeutics Inc. (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement (the “**Registration Statement**”) be accelerated to February 13, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling William Collins at (617) 570-1447. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “**Commission**”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: William Collins, by facsimile to (617) 321-4422.

If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.

Sincerely,

TCR<sup>2</sup> THERAPEUTICS INC.

/s/ Garry Menzel

Garry Menzel

President, Chief Executive Officer

cc: Garry Menzel, President and Chief Executive Officer, *TCR<sup>2</sup> Therapeutics Inc.*  
William Collins, Esq., *Goodwin Procter LLP*  
Mitchell Bloom, Esq., *Goodwin Procter LLP*